Correction to Lancet Infect Dis 2021; published online Jan 21. https://doi.org/10.1016/S1473-3099(20)30942-7

Ella R, Vadrevu KM, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis 2021; published online Jan 21. https://doi.org/10.1016/S1473-3099(20)30942-7—In this Article, the Role of the funding source has been updated to “The funder of the study had no role in data collection, data analysis, data interpretation, or writing of the statistical report, but was involved in study design. Data cleaning and analysis was conducted by a third party contract research organisation (Sclin Soft Technologies). Masked laboratory assessments were done at the respective laboratories and masked data sheets were sent to the contract research organisation for decoding and analysis. The unmasked randomisation list was not shared with the sponsor. All authors had full access to masked data in the study and had final responsibility for the decision to submit for publication“. This correction has been made to the online version as of Feb 23, 2021, and will be made to the printed Article.